Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Parallel-Cohort Phase 1 Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute Graft Versus Host Disease

Trial Profile

A Randomized, Parallel-Cohort Phase 1 Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute Graft Versus Host Disease

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Itacitinib (Primary) ; Methylprednisolone; Prednisone
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Proof of concept
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 01 Aug 2022 Results deriving Plasma samples from (identification cohort; NCT02614612, n=25) and deriving data fromNCT03139604- a validation cohort; evaluating biomarker signature predicting complete response to itacitinib and corticosteroids in acute graft-versus-host disease, published in the British Journal of Haematology
    • 10 Dec 2019 Results of proteomic analysis to identify potentially predictive biomarkers by using data from this study (n=25) presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Mar 2019 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top